🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

187 results for “Roche” Clear

  1. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Roche Registration Limited

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  2. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594

    Roche Registration Limited

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  3. RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Roche Registration Limited

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  4. RO5541267

    Roche Registration Limited

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    phase 3 small molecule active

    1 trial

  5. RO7046015, Placebo Prasinezumab

    Roche Registration Limited

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  6. RO7046015, RO7046015, RO7046015 Placebo

    Roche Registration Limited

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  7. RO7047650, Tecentriq 1 200 mg concentrate for solution for infusion

    Roche Registration Limited

    Renal cell carcinoma (RCC)

    phase 3 small molecule active

    1 trial

  8. RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D

    Roche Registration Limited

    Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. RO7790121 Placebo, RO7790121

    Roche Registration Limited

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  10. RO7790121, RO7790121 Placebo

    Roche Registration Limited

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  11. RO7790121, RO7790121 Placebo

    Roche Registration Limited

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  12. RO7795068, RO7795068, RO7795068 Placebo, RO7795068, RO7795068, RO7795068, RO7795068

    Roche Registration Limited

    Obesity or Overweight and Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  13. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Roche Registration Limited

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Roche Registration Limited

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  15. Satralizumab, Satralizumab

    Roche Registration Limited

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  16. Sutent 50 mg hard capsules, Alectinib (Alecensa), Sutent 12.5 mg hard capsules, Cotellic, Sutent 25 mg hard capsules, RO7047650, Cotellic, Alecensa 150 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, Zelboraf, Sutent 12.5 mg hard capsules, Venclexta, Venclyxto, Alecensa 150 mg hard capsules, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, RO7250726, Sutent 25 mg hard capsules, ALIMTA 500 mg powder for concentrate for solution for infusion, Sutent 50 mg hard capsules, Ze

    Roche Registration Limited

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  17. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  18. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Roche Registration Limited

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  19. Tecentriq 1 200 mg concentrate for solution for infusion

    Roche Registration Limited

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  20. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Roche Registration Limited

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Roche Registration Limited

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  22. Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab

    Roche Registration Limited

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  23. Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182

    Roche Registration Limited

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  24. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Roche Registration Limited

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources